Improving the conditioning regimen in multiple myeloma
Mené sur 205 patients atteints d'un myélome multiple, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du busulfan au melphalan en traitement de conditionnement préalable à une greffe autologue de cellules souches hématopoïétiques (durée médiane de suivi : 22,6 mois)
Multiple myeloma remains incurable for most patients, although the improvement in overall survival is evident for all physicians who treat patients with multiple myeloma every day. This improvement was initially restricted to young patients, and mainly associated with the introduction of autologous stem cell transplantation in the 1980s. This therapeutic strategy was the first major advance that occurred since the use of melphalan and prednisone for multiple myeloma treatment
The Lancet Haematology , commentaire, 2018